Literature DB >> 21656380

MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status.

Guang Yang1, Ruyou Zhang, Xiaofeng Chen, Yulong Mu, Jing Ai, Chen Shi, Yaohua Liu, Changbin Shi, Lihua Sun, Nikolai G Rainov, Hulun Li, Baofeng Yang, Shiguang Zhao.   

Abstract

MicroRNAs are single-stranded small non-coding RNA molecules which regulate mammalian cell growth, differentiation, and apoptosis by altering the expression of other genes and play a role in tumor genesis and progression. MiR-106a is upregulated in several types of malignancies and provides a pro-tumorigenic effect. However, its role in glioma is largely unknown. Our findings demonstrate that the low expression of miR-106a in human glioma specimens is significantly correlated with high levels of E2F1 protein and high-grade glioma. Here, we present the first evidence that miR-106a provides a tumor-suppressive effect via suppressing proliferation of and inducing apoptosis in human glioma cells. We further show that E2F1 is a direct functional target of miR-106a, suggesting that the effect of miR-106a on the glioma suppressive effect may result from inhibition of E2F1 via post-transcriptional regulation. In addition, our results reveal that miR-106a can increase p53 expression via E2F1 inhibition, whereas the effect of miR-106a on the proliferation of glioma cells is independent of p53 status. Further investigations will focus on the therapeutic use of miR-106a-mediated antitumor effects in glioma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656380     DOI: 10.1007/s00109-011-0775-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  34 in total

1.  Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker.

Authors:  Hui Zhou; Jun-Ming Guo; Yan-Ru Lou; Xin-Jun Zhang; Fa-De Zhong; Zhen Jiang; Jia Cheng; Bing-Xiu Xiao
Journal:  J Mol Med (Berl)       Date:  2010-03-28       Impact factor: 4.599

2.  IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.

Authors:  Atsushi Natsume; Dai Ishii; Toshihiko Wakabayashi; Takaya Tsuno; Hisashi Hatano; Masaaki Mizuno; Jun Yoshida
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

3.  Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.

Authors:  T Komata; Y Kondo; S Koga; S C Ko; L W Chung; S Kondo
Journal:  Gene Ther       Date:  2000-12       Impact factor: 5.250

4.  Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.

Authors:  Marta M Alonso; Juan Fueyo; Jerry W Shay; Kenneth D Aldape; Hong Jiang; Ok-Hee Lee; David G Johnson; Jing Xu; Yasuko Kondo; Takao Kanzawa; Satoru Kyo; B Nebiyou Bekele; Xian Zhou; Janice Nigro; J Matthew McDonald; W K Alfred Yung; Candelaria Gomez-Manzano
Journal:  J Natl Cancer Inst       Date:  2005-11-02       Impact factor: 13.506

5.  Altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach.

Authors:  Walter Pavicic; Esa Perkiö; Sippy Kaur; Päivi Peltomäki
Journal:  Mol Med       Date:  2011-02-09       Impact factor: 6.354

Review 6.  Tumor initiating cells in malignant gliomas: biology and implications for therapy.

Authors:  Costas G Hadjipanayis; Erwin G Van Meir
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

7.  Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency.

Authors:  Kathy Keck; Esther M Volper; Ryan M Spengler; Dang D Long; Chi Y Chan; Ye Ding; Anton P McCaffrey
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

8.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

Review 9.  Advances in the genetics of glioblastoma: are we reaching critical mass?

Authors:  Benjamin Purow; David Schiff
Journal:  Nat Rev Neurol       Date:  2009-07-14       Impact factor: 44.711

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  47 in total

Review 1.  E2F1: a promising regulator in ovarian carcinoma.

Authors:  Lei Zhan; Yu Zhang; Wenyan Wang; Enxue Song; Yijun Fan; Bing Wei
Journal:  Tumour Biol       Date:  2016-01-09

Review 2.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 3.  Glioblastoma: exosome and microRNA as novel diagnosis biomarkers.

Authors:  L Saadatpour; E Fadaee; S Fadaei; R Nassiri Mansour; M Mohammadi; S M Mousavi; M Goodarzi; J Verdi; H Mirzaei
Journal:  Cancer Gene Ther       Date:  2016-11-11       Impact factor: 5.987

4.  CDA-2 induces cell differentiation through suppressing Twist/SLUG signaling via miR-124 in glioma.

Authors:  You-ke Xie; Shao-fen Huo; Gong Zhang; Fu Zhang; Zu-ping Lian; Xiong-lin Tang; Chuan Jin
Journal:  J Neurooncol       Date:  2012-08-24       Impact factor: 4.130

5.  Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma.

Authors:  Feng Zhi; Naiyuan Shao; Rong Wang; Danni Deng; Lian Xue; Qiang Wang; Yi Zhang; Yimin Shi; Xiwei Xia; Suinuan Wang; Qing Lan; Yilin Yang
Journal:  Neuro Oncol       Date:  2014-08-18       Impact factor: 12.300

6.  miR-106a suppresses tumor cells death in colorectal cancer through targeting ATG7.

Authors:  Haibin Hao; Guangfeng Xia; Chao Wang; Fuping Zhong; Laipeng Liu; Dong Zhang
Journal:  Med Mol Morphol       Date:  2016-12-15       Impact factor: 2.309

7.  Pilot Study of Whole Blood MicroRNAs as Potential Tools for Diffuse Low-Grade Gliomas Detection.

Authors:  Catherine Gozé; Christelle Reynes; Lionel Forestier; Robert Sabatier; Hugues Duffau
Journal:  Cell Mol Neurobiol       Date:  2017-08-16       Impact factor: 5.046

8.  MiR-106a is an independent prognostic marker in patients with glioblastoma.

Authors:  Shiguang Zhao; Guang Yang; Yulong Mu; Dayong Han; Chen Shi; Xin Chen; Yifan Deng; Daming Zhang; Lu Wang; Yaohua Liu; Xu Hou; Chunlei Wang; Jianing Wu; Huailei Liu; Ligang Wang; Guang Zhang; Jiping Qi; Xiang Fang; Changbin Shi; Jing Ai
Journal:  Neuro Oncol       Date:  2013-02-14       Impact factor: 12.300

9.  mir-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells.

Authors:  Daming Zhang; Guang Yang; Xin Chen; Chunmei Li; Lu Wang; Yaohua Liu; Dayong Han; Huailei Liu; Xu Hou; Weiguang Zhang; Chenguang Li; Zhanqiang Han; Xin Gao; Shiguang Zhao
Journal:  J Mol Neurosci       Date:  2014-01-28       Impact factor: 3.444

10.  MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IκBα both in vitro and in vivo.

Authors:  Guang Yang; Dayong Han; Xin Chen; Daming Zhang; Lu Wang; Chen Shi; Weiguang Zhang; Chenguang Li; Xiaofeng Chen; Huailei Liu; Dongzhi Zhang; Jianhao Kang; Fei Peng; Ziyi Liu; Jiping Qi; Xin Gao; Jing Ai; Changbin Shi; Shiguang Zhao
Journal:  Neuro Oncol       Date:  2014-01-23       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.